OP20: Postoperative endoscopic recurrence after resection of Crohn’s terminal ileitis with Kono-S or side-to-side functional end anastomosis: results of a Multicenter Prospective Randomized TrialECCO'24 Stockholm 2024
OP22: Topical Sphingosine-1-Phosphate (S1P) Receptor 1 Modulation Regulates Gut Angiogenesis in Inflammatory Bowel DiseasesECCO'24 Stockholm 2024
OP23: Guselkumab induction restores intestinal immune homeostasis and promotes epithelial repair in moderately to severely active Ulcerative ColitisECCO'24 Stockholm 2024
OP25: Dual activation of GCGR/GLP1R signaling ameliorates intestinal fibrosis via metabolic regulation of histone H3K9 lactylation in epithelial cellsECCO'24 Stockholm 2024
OP26: Programmable probiotic local delivery of anti-TNF-α nanobody to alleviate DSS-induced colitisECCO'24 Stockholm 2024
OP27: Oxalyl-CoA decarboxylase is a major and specific virulence factor for Adherent Invasive Escherichia coliECCO'24 Stockholm 2024
OP28: Defective STAT3 signaling in refractory Very Early Onset Inflammatory Bowel Disease is associated with a transcriptional signature which predicts response to anti-IL23-based therapiesECCO'24 Stockholm 2024
OP29: Haematopoietic stem cell gene therapy as a treatment for severe Crohn’s Disease associated with pathogenic NOD2 genetic variantsECCO'24 Stockholm 2024
OP30: Endothelial cell-mediated smooth muscle hyperplasia in Crohn’s disease intestinal strictures: Caveolin 1 as a potential therapeutic targetECCO'24 Stockholm 2024
OP31: Single-cell analyses identify immune and stromal signatures of perianal fistulizing Crohn's DiseaseECCO'24 Stockholm 2024
OP32: TWIST1-mediated fibroblast activation protein (FAP)-expressing fibroblasts drives fibrosis in Crohn’s DiseaseECCO'24 Stockholm 2024
OP33: Mechanistic insights on the role of ultra processed foods as a trigger/fuel for IBDECCO'24 Stockholm 2024
OP34: Risk of Disease Recurrence and Re-resections in Crohn's Disease Patients Undergoing Primary Bowel Resection: A Population-Based StudyECCO'24 Stockholm 2024
OP35: Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 studyECCO'24 Stockholm 2024
OP36: Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE TrialECCO'24 Stockholm 2024
OP37: Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn's Disease. Multicenter study based on the ENEIDA registry of GETECCU.ECCO'24 Stockholm 2024